Kornimate/medical-research-clean huggingface dataset:
manhattan hiv/hepatology brain bank

Conditions: HIV; Hepatitis

Summary: description: the manhattan hiv/hepatology brain bank (mhbb) was established in 1998 as a resource for the aids research community. the mhbb was created to act as a center for the provision of pre- and post-mortem tissues and body fluids from hiv infected persons. it has recently expanded its goals to assist in the elucidation of liver disease-induced nervous system disorders. the mhbb is dedicated to improving the understanding of hiv and hepatitis c and thereby, improving the lives of patients living with hiv and/or hepatitis c. participation is voluntary and can be stopped at any time. benefits: this is an observational study; no experimental procedures, devices or drugs are used. all enrolled patients undergo regular examinations by physicians, nurses, and neuropsychologists who specialize in the problems that hiv and hcv can cause. taking part in this study may result in the detection of brain, muscle, or spinal cord disease for which treatments may be available. participants may receive no direct benefit from this study. however, knowledge gained from this research may, in the future, help others who suffer from hiv/aids and/or liver disease. participants agree to autopsy and organ donation upon demise by signing an anatomical gift consent document.


Eligibility criteria:
inclusion criteria: cd4 \ 12 weeks apart. hemoglobin \<10 g/dl. albumin \<3.2 g/dl. cmv end-organ disease disseminated mac pml aids dementia complex wasting (\>30% of lean body mass) visceral kaposi's sarcoma lymphoma-systemic of cns chf major systemic illness with poor prognosis (as determined by primary physician). exclusion criteria: - \<18 years old not willing to sign an anatomical gift consent for autopsy and organ donation upon demise.
cardiovascular risk and chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (cvr) in copd patients, using multivariate analysis.

reduced lung function is a major risk factor for cardiovascular mortality (cv), regardless of age, sex and history of smoking. similarly, cv events are known causes of mortality in patients with chronic obstructive pulmonary disease (copd). the investigators propose to determine the parameters influencing the evolution of cv risk in a cohort of copd patients followed over 5 years. for this the investigators will study the role of inflammation, oxidative stress, and vascular, respiratory and peripheral muscle function parameters. in order to study a sufficient number of patients the investigators propose to group data from two cohorts: a first cohort of 121 copd patients that already exists (currently closed to inclusions but still undergoing follow-up (nct00404430)) and a new cohort of 150, decompensated or not, copd patients. this study is of major scientific interest and will enable to obtain extremely important information to better understand copd.

Eligibility criteria:
inclusion criteria: for patients with stable copd: * men or women aged 18 to 85 * fev1/fvc \< 70% or proven bpco * patients who have given their free and informed consent in writing for patients with decompensated copd: * men or women aged 18 to 85 * fev1/fvc \< 70% or proven bpco * at the time of acute respiratory failure (arf), when admitted to hospital: * respiratory rate \> 25 cycles per minute * paco2 \> 45 mmhg * blood ph \< 7.35 * when included in the study: * ph \> 7.33 at the end of arf, 2 days in a row, or 3 to 7 days post-d1 decompensation (admission to the hospital) * fever \< 38.5°c * patients who have given their free and informed consent in writing exclusion criteria: * obvious evolving infection or crp \> 100 mg/l * cardiac decompensation considered the main cause of decompensation or chronic heart failure with lvef \< 45% * evolving neoplasia * on antioxidants: n-acetyl-cysteine, selenium, vit. c, vit. e * pregnant or nursing women * patients under tutorship or curatorship * patients participating in a drug clinical research study * patients not affiliated to the french social security system (or equivalent) * patients deprived of liberty or hospitalized without consent.

Keywords: chronic obstructive pulmonary disease cardiovascular risk inflammation oxidative stress peripheral muscle function
chemotherapy plus immunotherapy combined with sbrt as neoadjuvant therapy for patients with resectable nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: in this study, patients with egfr/alk wild-type, resectable locally advanced nsclc are expected to receive 1 cycle of chemoimmunotherapy as neoadjuvant therapy, followed by sbrt to the primary lung lesion, and chemoimmunotherapy for 2 cycles. surgical treatment will be given within 4-6 weeks after the last cycle of chemoimmunotherapy, then immunotherapy maintenance for 1 year.


Eligibility criteria:
inclusion criteria: 1. histologically or pathologically confirmed, newly diagnosed non-small cell lung cancer patients; 2. age ≥18 years; 3. (eastern cooperative oncology group, ecog) (performance status, ps) score 0-1; 4. according to the 8th-9th edition of (american joint committee on cancer, ajcc) (stage ii-iiia, for stage iiib included t3-4n2, t4 only included tumor \> 7cm); 5. puncture or biopsy samples were tested egfr/alk negative; 6. surgically or potentially resectable after discussion by multidisciplinary team (mdt); 7. who has not received systemic antitumor therapy and has not received chest radiotherapy; 8. evaluable lesions in the lung or mediastinum; 9. the organ function level should meet the following criteria one week before enrollment: 1) bone marrow function: hemoglobin ≥80g/l, white blood cell count ≥4.0\*10\^9/l or neutrophil count ≥1.5\*10\^9/l, platelet count ≥100\*10\^9/l; 2) liver: total serum bilirubin level ≤1.5 times the normal upper limit, when serum total bilirubin level \> 1.5 times the normal upper limit, direct bilirubin level ≤ normal upper limit, aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤2.5 times the normal upper limit; 3) kidney: blood creatinine level \< 1.5 times the normal upper limit or creatinine clearance ≥50ml/min, urea nitrogen ≤200mg/l; serum albumin ≥30g/l; 10. male/female of childbearing age agrees to use contraception during the trial period (surgical ligation or oral contraceptives/iuds + condom contraception); 11. sign informed consent. exclusion criteria: 1. patients with severe dysfunctions of the heart, lungs and other organs who are not suitable for surgery; 2. patients with severe autoimmune diseases: active inflammatory bowel disease (including crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (such as wegener's granuloma), etc; 3. other malignancies within 5 years (excluding non-melanoma skin cancer and cervical cancer); 4. patient with active infection, heart failure, heart attack, unstable angina pectoris or unstable arrhythmia within the last 6 months; 5. congenital or acquired immunodeficiency disorders include human immunodeficiency virus (hiv) or a history of organ transplantation or allogeneic stem cell transplantation; 6. patients treated with other immunological agents, chemotherapy agents, other drugs in clinical trials and long-term cortisol therapy were excluded; 7. patients who are allergic or contraindicated to pd-1 inhibitors.

Keywords: nsclc locally advanced resectable sbrt immunotherapy
evaluation of a double balloon interventional platform (dilumen) for complex colonic esd

Conditions: Colonic Polyp

Summary: the purpose of this randomized study is to compare esd procedural time and cost facilitated with a dual balloon accessory device versus esd procedures performed without the accessory device. study is designed to detect if the double balloon interventional platform helps to perform removal of benign complex colonic lesions safer and in more efficient way.

this is a prospective, post-market, randomized clinical trial comparing colonic esd procedures utilizing the dilumen™ endolumenal interventional platform to colonic esd procedures that are performed without use the dilumen™ device. the study participants will be randomly assigned to study group and control group the treatment group will consist of up to 100 subjects treated with the dilumen™ device. the control group will consist of up to 100 subjects treated without dilumen™ device. assessments will include procedure timepoints, anesthesia use, polyp location and classification, over-all cost assessment, and general complications. the primary outcome will be analyzed using parametric statistics to compare the means of the study and control groups. p-values and confidence intervals will be reported. descriptive and summary statistics will also be employed. secondary outcomes will be summarized with descriptive statistics.

Eligibility criteria:
inclusion criteria: 1. men or women 18-85 years of age. 2. have ability to understand the requirements of the study and provide written informed consent 3. suspected complex adenomatous polyps in the large intestine defined as sessile or polypoid lesions 2 cm and larger in size. 4. no medical contraindication to endoscopic submucosal dissection (esd). exclusion criteria: 1. contraindication to colonoscopy, such as active colitis, diverticulitis, perforation, or stricture. 2. history of open or laparoscopic colorectal surgery. 3. history of inflammatory bowel disease (ibd). 4. any medical or surgical condition that would preclude the endoscopic removal of the polyp. 5. anatomy or other factors that prohibit safe access to the large intestine such as previous radiation therapy to the affected area, known colonic strictures, extensive colonic diverticuli, etc. 6. history of aids, hiv, or active hepatitis. 7. history of mental illness, including psychological or neurological conditions (addiction to substances such as alcohol. e.g.) that in the investigator's opinion would pre-empt their ability or willingness to participate in the study. 8. patients who are pregnant or lactating. 9. currently involved in another investigational product for similar purposes.

Keywords: endoscopic submucosal dissection
teleable to reduce post-stroke sedentary behavior

Conditions: Stroke

Summary: the goal of this clinical trial to test whether a remotely delivered behavioral activation-based intervention called "teleable" works better than a health education intervention for (1) reducing sitting time and (2) improving health-related quality among adults who were diagnosed with stroke within the past 12 months. participants in this study will: * complete questionnaires at weeks 1, 8, and 24 * wear an activpal monitor at weeks 1, 8, and 24 * participate in the teleable intervention (12 sessions) or the health education intervention (6 sessions) * complete an interview at week 24


Eligibility criteria:
inclusion criteria: * age: 18 years or older * diagnosis: stroke diagnosis ≤12 months prior to study enrollment * ≥6 hours of sedentary behavior on a typical weekday (sedentary behavior questionnaire) * able to walk 150 feet or more without physical assistance from another person, with or without assistive device (assessed by functional independence measure, mobility score ≥5) * able to access an electronic device (smartphone, tablet, or computer) that is compatible with a videoconferencing application * able to identify a support person with whom they have a face-to-face interaction at least one time per week. * able and willing to participate fully in the study and provide informed consent exclusion criteria: * currently receiving care in an inpatient rehabilitation, transitional care unit, or skilled nursing facility * severe cognitive or communication impairments (inability to respond accurately to complete study telephone screening or complete informed consent) * comorbid neurodegenerative disorder (e.g. parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, alzheimer's disease, huntington's disease, glioblastoma) * comorbid cancer, currently undergoing chemotherapy or radiation treatment * comorbid major depressive disorder (patient health questionnaire-2, score ≥2) * received inpatient treatment or hospitalized for psychiatric condition and/or alcohol or substance abuse within the past 12 months * diagnosis of a terminal illness and/or currently receiving hospice care * currently pregnant or expecting to become pregnant in the next 6 months * history of skin sensitivity that precludes the use of medical tape necessary for adherence to activity monitor measure * inability to speak, read, or understand english * concurrent participation in any other rehabilitation intervention research study (including cognitive and/or physical rehabilitation studies) * investigator discretion for safety or adherence reasons

Keywords: sedentary behavior physical activity behavioral activation activity engagement occupational therapy rehabilitation
outcome of chest trauma patients in one year in sohag university hospital

Conditions: Chest Trauma Patients

Summary: the history of chest trauma is as old as that of man himself. one of the earliest writings about chest trauma is found in the edwin smith surgical papyrus, written in 3000 bc. over the last century, there has been considerable reduction in the mortality of chest trauma owing to improved pre-operative care, availability of positive pressure ventilation, increasing availability of antibiotics, improvement of radiological techniques and improved lung toilets measures etc. chest trauma implies trauma to any or combination of different thoracic structures, which can be divided into 4 anatomical regions i.e. the chest wall, the pleural space, the lung parenchyma, and the mediastinum. trauma is one of the top ranking causes of accidental or unnatural deaths. chest trauma is a significant source of morbidity and mortality worldwide. overall, it accounts for 25%-30% of all trauma related deaths and is implicated in an additional 25% of patients, who died from injuries. in most cases, blunt chest trauma is by far the commonest and road traffic accidents account for 70%-80% of such injuries. fire-arm injuries, falling from height, blast, stabs, and various acts of violence are the other causative mechanisms.


Eligibility criteria:
inclusion criteria: * males and females * adults and children * isolated chest trauma * polytraumatized patients * penetrating chest trauma * blunt chest trauma exclusion criteria: * patients presented with cardiac arrest * patients presented dead * patients with glasco coma scale 5 or less * patients with sever abdominal injuries
safety and efficacy of bilateral superficial cervical plexus block in thyroidectomy

Conditions: Pain; Postoperative

Summary: with thyroid surgery being performed as an ambulatory procedure, most recent studies concerning post thyroidectomy analgesia are focused on regional techniques such as bilateral superficial cervical plexus block (bscpb) and bilateral combined superficial and deep cervical plexus block. but, data regarding the efficacy of bscpb are controversial. hence the investigators compared the efficacy of bscpb with 0.25% bupivacaine with or without clonidine in thyroidectomy, as preemptive analgesia. the hypothesis was bupivacaine with the addition of clonidine would help in reducing postoperative pain and thereby reduce the need for postoperative analgesia.

to find out if addition of bscpb to general anesthesia with bupivacaine with or without clonidine prolongs the time needed for postoperative analgesic and facilitate to perform thyroidectomy as a day care procedure and to see if clonidine reduces postoperative nausea and vomiting.

Eligibility criteria:
inclusion criteria: * consenting consecutive euthyroid patients undergoing elective thyroidectomy under general anesthesia, of either genders and more than 18 years of age, belonging to the asa class i and ii. exclusion criteria: * patients unable to understand visual analog pain score (vas) or unable to use patient controlled analgesia (pca). * patients with malignancy requiring block dissection or with substernal goiters - contraindications to superficial cervical plexus block like allergy to local anesthetics, bleeding diatheses and local infection or sepsis. * contraindications to morphine like bronchial asthma and hypothyroidism. * sensitivity to the anesthetic agent used or intolerance to the medications used in the study. * patients who received steroids or opioids or other analgesics recently. * patients with history of stridor.

Keywords: cervical plexus block thyroidectomy postoperative analgesia
minimal clinically important difference of the box and block test in parkinson

Conditions: Parkinson Disease

Summary: the aim of this study is to examine the level of clinical change in gross manual skills of parkinson's patients who receive conventional physiotherapy. for this purpose, the box-block test will be used, and the amount of change that must occur in the patient's hand functions will be determined for the test to be considered clinically meaningful. patients will continue their routine physical therapy sessions and the researchers will not interfere with this program. the treatment program will be created by the clinical specialist physician and physiotherapist. upper extremity rehabilitation programs for parkinson's patients generally consist of methods such as stretching, strengthening, reaching, coordination and recreational activities. patients will receive physiotherapy for 30 sessions.


Eligibility criteria:
inclusion criteria: * being hoehn \& yahr stage between 1-3, * individuals in the "on" phase, * those who were not exposed to any physiotherapy intervention during the initial assessment exclusion criteria: * mini-mental status assessment \&lt; 24 points; * presence of severe dyskinesia, * those who experience fluctuations in the on-off phase, * those who have undergone stereotaxic brain surgery for parkinson's, * individuals with changes in dopamine dose within three months, * presence of unstable cardiac and respiratory disease * those with an orthopedic problem or a history of surgery affecting upper extremity performance.

Keywords: parkinson box and block test minimal clinically important difference
safety and potential bioactivity of clbs16 in patients with coronary microvascular dysfunction and without obstructive coronary artery disease

Conditions: Coronary Microvascular Dysfunction

Summary: this clinical trial will explore the safety and effect of gcsf-mobilized autologous ex vivo selected cd34 cells for the treatment of cmd in adults currently experiencing angina and with no obstructive coronary artery disease. eligible subjects will receive a single intracoronary infusion of clbs16.


Eligibility criteria:
inclusion criteria: * men or women age ≥18 * history of and currently experiencing angina at least 3 times per week * no obstructive coronary artery disease * on stable medical therapy for 30 days prior to enrollment * must agree to use a reliable and acceptable method of contraception for the duration of participation * written informed consent exclusion criteria: * myocardial infarction within 90 days * prior evidence of obstructive heart disease including pci or cabg (or planned pci or cabg) * diagnosis of other specific cardiac disease * must meet lvef and gfr requirements * current use of coumadin or doacs * hypersensitivity to g-csf, apheresis or study product components * positive for hiv, hepatitis b or hepatitis c * active inflammatory or autoimmune disease, or chronic immunosuppressive state * drug abuse * pregnant or lactating * malignant neoplasm within 5 years * history of sickle cell disease * participation in another clinical study within 90 days
the effect of "jinchuang ointment" (jco) on the treatment of wounds in patients with hansen's disease.

Conditions: Leprosy; Hansen's Disease; Wounds

Summary: this study aimed to evaluate the effect of a chinese herb complex "jinchuang ointment" (jco) on the treatment of chronic nonhealing wounds in patients with hansen's disease and its mechanism.

20 patients who were hospitalized at lo-sheng sanatorium, ministry of health and welfare, were recruited. ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the taiwan food and drug administration. besides, jco was applied once a day on the wounds. basic data of each case were collected, and a monthly wound record was used to follow the condition of the wound healing of these patients.

Eligibility criteria:
inclusion criteria: * hanson's patients * meet the definition of chronic wound exclusion criteria: * kidney disease * parathyroid disease * malignant tumors.

Keywords: leprosy hansen's disease (hd) jinchuang ointment (jco) wounds anti-inflammation
a pilot study of a new peg3350 dose formulation for use in constipated children

Conditions: Constipation

Summary: to evaluate the patient acceptance of a new peg3350 dose formulation in children currently treated with peg3350 powder for treatment of constipation.


Eligibility criteria:
inclusion criteria: * male or female constipated outpatients between the ages of 4 and 16 * currently taking a dose of peg 3350 powder up to a maximum of 17g per day that has been consistent for at least 4 weeks, or if less than 4 weeks, the investigator testifies that the patient is stable * current treatment is considered successful - defined as greater than 2 bowel movements per week with no accidents * are otherwise in good health, as judged by a physical examination * if female and of childbearing potential, patient must be using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so for the duration of the study * in the investigator's judgment, patient or guardian is mentally competent to sign an instrument of informed consent exclusion criteria: * patients who are impacted at baseline exam * patients with known or suspected perforation or obstruction * patients with a history of gastric retention, inflammatory bowel disease, bowel resection, or colostomy * patients with a known history of organic cause for their constipation * patients currently using medications known to cause constipation (these include opiates, antidepressants, ssri's, antimotility agents and anticholinergics) * patients who are breastfeeding, pregnant, or intend to become pregnant during the study * female patients of childbearing potential who refuse a pregnancy test * patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedure * patients with known allergy to peg or peg containing medications * patients who, within the past 30 days have participated in an investigational clinical study